Zapping tumors: electric fields tested against pancreatic cancer

NCT ID NCT07319910

TEMPORARILY_NOT_AVAILABLE Disease control Sponsor: NovoCure GmbH Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This program gives adults with locally advanced pancreatic cancer access to a device that delivers gentle electric fields to the abdomen, combined with standard chemotherapy. The goal is to see if this approach is safe and feasible while the device awaits FDA approval. Participants must be able to use the device themselves or with help from a caregiver.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

TTFields (electric fields) plus gemcitabine and nab-paclitaxel chemotherapy

What this could lead to

If it works, this could offer a new treatment option for people with locally advanced pancreatic cancer, potentially slowing tumor growth.

What could go wrong

This is an early access program, not a full trial, so effectiveness is not yet proven. The device requires daily wear and may cause skin irritation.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.